SkyView Investment Advisors LLC Makes New Investment in Drugs Made In America Acquisition II Corp. $DMII

SkyView Investment Advisors LLC acquired a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 250,000 shares of the company’s stock, valued at approximately $2,515,000. Drugs Made In America Acquisition II accounts for approximately 2.1% of SkyView Investment Advisors LLC’s portfolio, making the stock its 12th biggest position.

Several other large investors also recently bought and sold shares of DMII. Gabelli Funds LLC acquired a new stake in Drugs Made In America Acquisition II in the 1st quarter valued at about $1,609,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Drugs Made In America Acquisition II during the first quarter worth approximately $1,790,000. Clear Street Group Inc. purchased a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth approximately $1,797,000. Mint Tower Capital Management B.V. acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $2,475,000. Finally, Periscope Capital Inc. acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $2,628,000.

Drugs Made In America Acquisition II Stock Performance

Shares of Drugs Made In America Acquisition II stock opened at $10.17 on Tuesday. The company has a fifty day simple moving average of $10.12 and a 200-day simple moving average of $10.06. Drugs Made In America Acquisition II Corp. has a 12-month low of $9.86 and a 12-month high of $10.21.

Drugs Made In America Acquisition II (NASDAQ:DMII) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.07 EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a report on Tuesday, September 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.